More bad news for the blood-testing startup with the $9 billion valuation. The results of Theranos’s cholesterol tests varied enough from those done by the country’s two biggest lab companies (Quest Diagnostics and Laboratory Corp. of America) that “they could throw off doctors’ medical decisions,” reports the Wall Street Journal. The study, published Monday in the Journal of Clinical Investigations, found that the “results for total cholesterol were lower by an average of 9.3% than those produced by Quest and LabCorp.” MB
collectionsInnovation FestivalCurrent Issue
World Changing Ideas
New workplaces, new food sources, new medicine--even an entirely new economic system.
The major tech ecosystems that battle for our attention and dollars.
What’s next for hardware, software, and services.
The brave new world of automation, from AI to drones.
How our urban centers are building toward the future.
Most Creative People
See members of our Most Creative People in Business community: leaders who are shaping the future of business in creative ways.
An award-winning team of journalists, designers, and videographers who tell brand stories through Fast Company's distinctive lens.